Currently, the IVD industry is facing challenges such as stringent regulations, industry consolidation, new healthcare reforms, and ever-changing demographics. However, despite these challenges, the advent of new technologies and innovations has the potential to invigorate the growth of the IVD market. Molecular diagnostics, genomics, and next-generation sequencing are expected to be primary facilitators of this growth by providing new avenues for improved disease diagnosis, hence, redefining patient outcomes.

The global neurostimulation devices market consists of various leading manufacturers, small-medium enterprises, and emerging start-ups. With the increasing demand for neuromodulation technologies, companies have the opportunity to expand in the market through different strategic approaches. Some of the strategies followed by the leading contributors are regulatory approvals, collaborations, partnerships, mergers, acquisitions, and product launches. In the past four years (January 2016-May 2020), the market witnessed approximately 22 funding activities, five mergers and acquisitions, 12 new offerings (product launches), 19 partnerships, alliances, and business expansions, and 69 regulatory approvals. Among the different key developments, regulatory approvals of the neurostimulation devices from different regulatory bodies, and funding activities are constituting the dominant contributor’s strategies.

Cancer immunotherapy has significantly advanced in the past few years, and PD-1/PD-L1 immunotherapy has emerged out as one of the most prominent therapies. Many clinical trials have proved their significance, and many are still underway to find other cancers which can be treated with this therapy.

Patient centric applications are tools that enable connection between practitioners, patients, and their families ensuring appropriate decision making for respective patients. These apps are developed considering the needs and preferences of patients to manage their health effectively. Thus, increasing the quality and efficiency of wellness management, and disease as well as treatment management. Rise in transition from institution centric to patient centric care integrating electronic communication at all levels has increased the adoption of patientcentric apps across the healthcare industry. A well-designed patient care application has the ability to enhance the quality and efficiency of healthcare by assisting patients in managing their health in a better manner.

Peripheral artery disease (PAD) is a disease of blood vessels located outside the brain and heart. PAD occurs when plaque builds up in arteries that carry blood to the head, organs, and limbs. Plaque is made of fat, cholesterol, calcium, fibrous tissue, and other substances. PAD usually affects arteries in the legs, but it can also affect arteries that carry blood from heart to head, arms, kidneys, and stomach. The report provides dynamics and trends related to the global peripheral artery disease market. In addition, it presents estimations and forecast of the market. The study estimates revenue generated from sales of peripheral artery disease equipment. However, the report excludes revenue generated from post-sale services and service costs associated with the market.

The report provides market dynamics and trends related to the neurovascular devices market. Furthermore, it includes the study of revenue generated from sales of various types of neurovascular devices such as embolization devices, revascularization devices, thrombectomy devices, embolic protection devices, and accessory devices. In addition, the report is also segmented into disease pathology, which is divided into aneurysm, ateriovenous malformation, ischemic stroke, stenosis and others. This segmentation provides an idea about the use of various neurovascular devices in different types of neurovascular disorders. Furthermore, the report does not contain revenue generated from the sales of associated neurovascular services offered in the market.

The scope of the report is limited to revenue generated from sales of patient monitoring devices, which are used to monitor vital signs of patients during various procedures. The report excludes revenue generated from services provided by doctors, nurses, and other healthcare professionals. Recent advancements and developments in patient monitoring devices have enhanced efficiency of these medical devices. Drivers, restraints, and opportunities are explained in detail to understand the market dynamics. Key strategies adopted by potential market leaders to facilitate effective planning and decision-making are also discussed in the report. The global patient monitoring devices market is segmented on the basis of device type, end user, and region. By device type, it is divided into hemodynamic monitoring, neuro monitoring, cardiac monitoring, fetal & neonatal monitoring, respiratory monitoring, multi-parameter monitoring, remote patient monitoring, weigh monitoring, and temperature monitoring devices. On the basis of end users, it is segmented into hospitals & clinics, home settings, and ambulatory surgical centers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The scope of the pain management drugs market report includes revenue generated by drugs that are used for treatment of various pain conditions such as cancer pain, post-operative pain, and chronic pain. The revenue of different classes of drugs such as opioids, antidepressants, and anesthetics has been included in the report.

Personal care ingredients are the raw materials which are used in the manufacturing of skin care products worldwide. These ingredients can be used in the skin care products as an anti-fungal agent, anti-ageing agent, skin conditioning agent, and others. They can also be classified as active and inactive ingredients. Active ingredients include anti-ageing agents, exfoliants, conditioning agents, and UV protecting agents whereas, inactive ingredients include surfactants, preservatives, colorants, and polymer ingredients. Rise in disposable incomes strengthened the purchasing power of consumers along with change in standard of living, which is expected to drive the growth of the personal care ingredients market during 2020-2027. In addition, increase in consumer awareness toward multi-purpose products fuel the growth of the market. However, side effects of chemical-based personal care products and stringent government regulations are the key factors hampering the growth of the market during the forecast period. Whereas, innovations in skin care products and rise in health awareness & increase in demand for personal care products are expected to create opportunities in the global personal care ingredients market during the analyzed timeframe.

本周辉瑞宣布 mRNA 疫苗临床表现优异，或引发人们对于前期受益于 疫情的医药子版块及个股后续业绩的疑虑。我们认为短期来看寻求与疫 情关联度较低的板块作为“避风港”或为明智之举。我们此前持续推荐 的 CDMO 板块作为因全球产业链转移持续进行而景气度高，业绩与疫 情相关度低且不受带量采购等政策影响的子行业，兼具短期及长期配置 逻辑，是当前理想的行业“避风港”及长期看好的优质资产。

从申万医药指数2003年设立以来的17年来看，有5个年份收益 低于沪深300指数，相对指数的年度战胜率为70.6%，医药行业无疑是好 的赛道。从这个角度出发，如果投资者只是想要选择跑赢大盘的医药基 金，那么医药指数基金就是不错的选择。2010年市场上第一只医药行业 主题基金孕育而生，当前市场上共有131只医药基金（按份额层面统计）。

自上而下看，投融资环境受到全球流动性、国内科创板 及疫情的影响，保持了良好势头，2020Q3 国内外医疗健康融资创历史 新高，好于我们之前的预期。

国外GLP-1RA实现高速增长，加速实现胰岛素替代。2019年GLP-1RA全球销售额超100亿美元，在全球降糖药市场中占比达到 19%。近十年，GLP-1类药物在全球保持了39.7%的复合增长率，高于胰岛素类14.4%的增速及口服降糖药11.7%的增速。2020年上半 年，全球糖尿病巨头诺和诺德的GLP-1RA逆势增长28%，胰岛素却同比下降3%，可见大多数情况下GLP-1RA替代胰岛素是大势所趋。

根据国家统计局的最新数据，2020年1-8月行业累计营业收入达1.50万亿，同比增长0.1%，增速较2019年同期下降8.4个百分点；2020 年1-8月行业利润为2140.1亿元，同比增长7.4%，增速较2019年同期下降2.1个百分点。

多因素推动专科医疗服务发展，各细分表现亮眼：我国专科医疗服务在政策推动、高人口基数支撑以及消费能力、保健意识提升等因素的推动下 迎来了蓬勃发展，从2008年的3437家提升至2018年的7900家，十年复合增速8.7%，成为我国医疗资源非常重要的一部分，尤其是民营专科医院数 量十年复合增速达到13.77%，同时农村地区的专科医院也呈现较快增长态势，以满足我国农村地区对医疗资源的需求。

医药生物行业整体业绩:2020Q3业绩增速有所回升。2020年前三季度，SW 医药生物行业（剔除B股，共353家样本公司）实现营业总收入13519.43亿 元，同比增长2.44%；实现归属于母公司股东的净利润1315.2亿元，同比增 长24.84%；实现扣非归母净利润1141.7亿元，同比增长28.59%。2020Q3， SW医药生物行业分别实现营收和归母净利润为5558.78亿元和573.85亿 元，分别同比增长9.4%和39.15%，Q3业绩增速较Q1和Q2有所回升。细分 板块中，前三季度业绩表现最好的是医疗器械，主要是受益疫情。化学原 料药、生物制品、医药商业和医疗服务业绩均实现正增长，化学制剂和中 药业绩仍有所下滑。从单季业绩来看，Q3化学原料药业绩增速环比有所回 落，医疗器械保持快增，化学制剂、中药、生物制品、医药商业和医疗服 务业绩增速环比均有所回升。

人血白蛋白（规格换算/10g）： 2020年1-10月，人血白蛋白批签发总量为4884万瓶(+18%)，其中国产人血 白蛋白批签发总量为1810万瓶(+4%)，占比为37%；进口人血白蛋白批签发总量为3073万瓶(+28%)，占比为63%。